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ABSTRACT 
S-acylation (palmitoylation) is the only fully reversible lipid modification of proteins however little is 
known about how protein S-acyltransferases (PATs) that mediate it are regulated. DHHC5 is a PAT that 
is mainly localised at the plasma membrane with roles in synaptic plasticity, massive endocytosis and 
cancer cell growth/invasion. Here we demonstrate that DHHC5 binds to and palmitoylates a novel 
accessory protein Golga7b. Palmitoylation of Golga7b prevents clathrin-mediated endocytosis of 
DHHC5 to stabilise it at the plasma membrane. Proteomic analysis of the composition of 
DHHC5/Golga7b-associated protein complexes reveals a striking enrichment in adhesion proteins, 
particularly components of desmosomes. We show that Desmoglein-2 and Plakophilin-3 are 
substrates of DHHC5 and that DHHC5/Golga7b are required for localisation of Desmoglein-2 to the 
plasma membrane and for desmosomal patterning. Loss of DHHC5/Golga7b causes functional 
impairments in cell adhesion suggesting these proteins have a wider role in cell adhesion beyond 
desmosome assembly. This work uncovers a novel mechanism of DHHC5 regulation by Golga7b and 
demonstrates a role for the DHHC5/Golga7b complex in the regulation of cell adhesion. 
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INTRODUCTION 
S-acylation (palmitoylation) is unique amongst post-translational modifications as it is the only fully 
reversible modification that involves the attachment of a lipid to a protein, in this case, to the side 
chain of cysteine residues via a thioester bond. While palmitoylation was discovered several decades 
ago as a modification of viral proteins [1], the progress in our understanding of palmitoylation has 
been slower than that for other modifications such as phosphorylation. For example, the regulation 
of the family of enzymes which attach the fatty acid onto proteins, palmitoyl acyltransferases (PATs) 
is still poorly understood. There are 23 PATs encoded in the human genome, all of which are integral 
membrane proteins (Korycka et al., 2012), with a range of cellular locations and tissue expression 
patterns [2]. They are also referred to as DHHC proteins as their characteristic active site motif 
contains the sequence Asp-His-His-Cys which is required for palmitoylation of substrates. However, it 
has been shown that in some cases, additional proteins are required for PAT activity. This was first 
demonstrated in yeast, where the palmitoylation of Ras, which is essential for its signalling and 
function [3], requires a complex of two proteins localised to the endoplasmic reticulum, Erf2 and Erf4 
[4]. Subsequently, it was discovered that in mammalian cells, DHHC9 requires the protein GCP16, also 
known as Golga7, to form a complex capable of palmitoylating Ras [5]. The mechanism by which Erf4 
acts on Erf2 was subsequently determined to involve stabilisation of the intermediate state where the 
acyl chain is transferred to the PAT before the final transfer of the acyl chain to the substrate [6].  
In a large scale affinity purification-mass spectrometry study, Golga7b was identified as a 
putative interactor of DHHC5 [7]. Golga7b is a member of the Erf4 protein family which is closely 
related to GCP16 (Golga7) with 61% sequence identity. This interaction has yet to be confirmed and it 
is unknown whether Golga7b could regulate DHHC5 in a manner analogous to how DHHC9 is regulated 
by GCP16. Interestingly, Golga7b was also identified as a putative palmitoylated protein in both 
humans and mice [8, 9], although confirmation of this palmitoylation and the identity of the cognate 
PAT is lacking. 
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 While the majority of PATs are localised to the Golgi, DHHC5 is localised to the plasma 
membrane [2] and in neurons, it cycles from the synaptic membrane to dendritic shafts in response 
to neuronal activity [10]. It is expressed in all tissues in mammals but it is highly enriched in the heart 
and the brain. It plays a role in the growth and invasion of certain types of non-small-cell lung cancer 
and DHHC5 knockdown reduces the growth and invasion of these types of tumours [11]. DHHC5 has 
few confirmed substrates, but it is known to palmitoylate the plasma membrane protein Flotillin-2 
(Flot2), which is enriched in cholesterol rich microdomains [12]. In the heart, DHHC5 it is a key player 
in the phenomenon of massive palmitoylation-dependent endocytosis (MEND) [13]. This process 
occurs when oxygen is reintroduced to cardiac muscle cells starved of oxygen and involves the 
endocytosis of a large proportion of the plasma membrane, giving DHHC5 a role in the recovery of 
heart muscle from periods of anoxia [14]. Additionally, an important role for DHHC5 in the regulation 
of the cardiac sodium pump through palmitoylation of phospholemman has been established [15].  
In neurons, DHHC5 is present at the post-synaptic density and knockout mice have defects in 
learning and memory [16]. DHHC5 is retained at the plasma membrane of the post-synaptic density 
through interactions with the scaffolding protein PSD-95 and the tyrosine kinase Fyn [10]. When 
neurons are activated by long-term potentiation, phosphorylation of DHHC5 by Fyn is reduced, DHHC5 
ŝƐ ůŽƐƚ ĨƌŽŵ ƚŚĞ ĐŽŵƉůĞǆ ĂŶĚ ŝƐ ĞŶĚŽĐǇƚŽƐĞĚ ƚŽ ĚĞŶĚƌŝƚŝĐ ƐƉŝŶĞƐ ǁŚĞƌĞ ŝƚ ƉĂůŵŝƚŽǇůĂƚĞƐ ɷ-catenin 
before both proteins are trafficked back to the plasma membrane at the post-synaptic density [10]. 
This type of controlled endocytic movement of DHHC5 has not been described for any other PAT, but 
does leave a number of open questions including the mechanism of endocytosis from the plasma 
membrane and whether a similar system of trafficking of DHHC5 to and from the plasma membrane 
is present in other cell types or is unique to neurons. 
We and others have identified a cluster of three palmitoylation sites in the C-terminus of 
DHHC5 (located just after its fourth transmembrane domain), some of which appear to be conserved 
in several other PATs [9, 17]. In brain extracts, DHHC5 exists in a predominantly palmitoylated form 
with several palmitoylated states apparent [9]. The function of palmitoylation at these sites is 
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unknown but we hypothesise that they may regulate DHHC5 localisation and/or stability. Indeed, 
recent work has established an important role for palmitoylation of the C-terminus of DHHC6 by 
DHHC16 in the regulation of its activity and turnover [18]. This region of DHHC5 is also involved in 
substrate recruitment; DHHC5 binds to and palmitoylates the sodium pump regulator 
phospholemman and this is dependent on a region of the C-terminus of DHHC5 just after its fourth 
transmembrane domain [15]. 
 A number of studies have reported that several proteins involved in both cell:cell and 
cell:matrix adhesion are palmitoylated and that this palmitoylation regulates localisation and function 
of these proteins [19-21]. Among adhesion protein complexes, desmosomes are notable as several 
components of the complex are palmitoylated [22]. Palmitoylation of plakophilin-3 (Pkp3) is essential 
for both its inclusion into desmosomes and is required for the efficient assembly of desmosomes. One 
of the two desmosomal cadherins, desmoglein-2 (Dsg2), is palmitoylated on a pair of cysteines [23]. 
Mutation of the palmitoylation sites of Dsg2 does not prevent the incorporation of Dsg2 into 
desmosomes but does cause a trafficking defect with a portion of Dsg2 localised to lysosomes. This 
shows that it is likely that palmitoylation plays a central role in desmosomal assembly, turnover and 
trafficking however it is unknown which PAT or PATs regulate this process. 
 Here we demonstrate that Golga7b interacts with DHHC5 and Golga7b palmitoylation 
regulates plasma membrane localisation of DHHC5. We have determined that the interaction between 
DHHC5 and Golga7b is controlled by the palmitoylation of the C-terminal tail of DHHC5. We also show 
that palmitoylation of Golga7b prevents internalisation of DHHC5 by AP2-regulated clathrin mediated 
endocytosis. Using affinity purification-mass spectrometry analysis we demonstrate that Golga7b 
defines the interactome of DHHC5 and contains known and novel substrates as well as regulators of 
DHHC5. Investigation of selected novel substrates revealed a central role for DHHC5 and Golga7b in 
cell adhesion; DHHC5 palmitoylates both Dsg2 and Pkp3 and loss of DHHC5 or Golga7b causes defects 
in cell adhesion. These results uncover a novel palmitoylation-dependent mechanism to control the 
localisation and function of DHHC5 and reveal an important new role for DHHC5 in cell adhesion. 
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RESULTS 
DHHC5 interacts with and palmitoylates a novel acessary protein Golga7b 
Initially, we set out to confirm whether Golga7b is indeed palmitoylated and if Golga7b interacts with 
DHHC5, as both of these results had come from large-scale studies and had not been validated by 
orthogonal methods [7, 9]. Initial attempts to express a palmitoylation-deficient mutant Golga7b in 
which cysteines in the sequence were mutated to alanines resulted in undetectable levels of 
expression of the construct by immunoblotting and immunofluorescence microscopy. As 
palmitoylation regulates the stability of some proteins, this can lead to degradation of palmitoylation-
deficient mutants [24]. Expression of mutant Golga7b with the addition of MG132 prevented 
degradation of mutant Golga7b (Fig 1a) and therefore, we included MG132 in all subsequent 
experiments with this and the WT Golga7b construct.. To measure palmitoylation we used an acyl-
biotin exchange (ABE) strategy [25] in which palmitoyl groups are selectively released from cysteine 
residues by hydroxylamine at neutral pH, these cysteine residues are biotinylated and enriched using 
streptavidin resin. Using this approach, we found that a C-terminally FLAG-tagged full length wild-type 
(WT) Golga7b is palmitoylated when expressed in HeLa cells, but when the cysteines in the sequence 
were mutated to alanines, this palmitoylation was lost (Fig 1A). Next, we sought to test whether 
DHHC5 could palmitoylate Golga7b using ABE plus/minus siRNA-mediated knockdown of DHHC5 
(Appendix Figure S1A). When compared to cells that are treated with a non-targeting siRNA, there 
was a significant reduction (to below the limit of dection) in the palmitoylation state of Golga7b when 
DHHC5 is depleted (Fig 1B). Ectopic expression of a WT DHHC5 construct in cells depleted of 
endogenous DHHC5 can rescue palmitoylation of Golga7b back to endogenous levels whilst expression 
of a catalytically dead DHHC5 mutant is unable to rescue the palmitoylation of Golga7b (Fig 1B-D). 
Although we cannot rule out that Golga7b may also be a target for other PATs, our data clearly indicate 
that that DHHC5 is the major PAT for Golga7b. 
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We sought to confirm the interaction between DHHC5 and Golga7b by co-
immunoprecipitation using N-terminally HA-tagged DHHC5 and FLAG-tagged WT and palmitoylation-
deficient mutant Golga7b constructs co-expressed in HeLa cells. DHHC5 immunoprecipitated both WT 
and mutant Golga7b (Fig 1E) indicating that the palmitoylation state of Golga7b does not affect its 
interaction with DHHC5. The same is also true for a catalytically inactive form of DHHC5 where the 
catalytic cysteine is mutated to a serine residue (DHHS5, Fig 1E). However, when the three 
palmitoylation sites present in the C-terminal tail of DHHC5 [9] are mutated, this mutant DHHC5 was 
unable to immunoprecipitate either the WT or mutant Golga7b (Fig 1E) suggesting that palmitoylation 
of DHHC5 is directly required for this interaction.  
To confirm that the interaction of DHHC5 and Golga7b occurs in vivo, we performed 
immunoprecipitations of endogenous DHHC5 and Golga7b from a mouse forebrain lysate. This 
demonstrated that DHHC5 is immunoprecipitated by endogenous Golga7b (Figure EV1A) and that 
endogenous DHHC5 can reciprocally immunoprecipitate Golga7b (Figure EV1B). We next confirmed 
that endogenous Golga7b is palmitoylated in this context using an ABE assay (Figure EV1C). These 
results demonstrate that DHHC5 and Golga7b interact in vivo and that DHHC5 is the major PAT for 
Golga7b. 
 
Co-expression of Golga7b regulates plasma membrane localisation of DHHC5 
We next confirmed that DHHC5 is localised to the plasma membrane [2] by staining for the 
endogenous protein in HeLa cells (Figure EV2A). However, when we overexpress DHHC5, we observe 
staining throughout the cell (Figure EV2B), indicating that mislocalisation occurs upon over-
expression. It has been reported that the over-expression of PATs can lead to their mislocalisation 
[26], which could suggest that factors that regulate their localisation need to be present in sufficient 
quantities to ensure proper localisation. We hypothesised that Golga7b might act as a regulator of 
DHHC5 and may be involved in the targeting or stabilisation of DHHC5 at the plasma membrane. To 
investigate this, we co-expressed DHHC5 with either WT or a palmitoylation-deficient mutant Golga7b 
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and performed immunofluorescence microscopy. When endogenous DHHC5 is depleted and a tagged 
version is co-expressed with WT Golga7b, the majority of DHHC5 is present at the plasma membrane 
(Figure 2A). This indicates that when DHHC5 is over-expressed alone, there is insufficient endogenous 
Golga7b present to either target DHHC5 to the plasma membrane or stabilise DHHC5 protein at the 
plasma membrane. Strikingly, when DHHC5 is co-expressed with mutant Golga7b which cannot be 
palmitoylated, the majority of DHHC5 is lost from the plasma membrane (Figure 2b). This indicates 
that palmitoylation of Golga7b is required for the maintenance of DHHC5 at the plasma membrane 
and when this is prevented, DHHC5 is mislocalised. 
 Co-expression of wild-type Golga7b with the catalytic mutant of DHHC5 (DHHS5), in cells 
depleted of endogenous DHHC5, causes a significant reduction in DHHS5 at the plasma membrane 
compared to WT DHHC5 (Fig 2C). This mislocalisation is likely caused by a reduction of Golga7b 
palmitoylation as its palmitoylation level is significantly reduced in cells expressing the catalytic 
mutant DHHS5 compared to WT DHHC5 (Fig 1B-D). Expression of DHHS5 with mutant Golga7b 
mimicked what we observed with WT DHHC5 (Fig 2D) in that there is significantly more DHHS5 at the 
plasma membrane when co-expressed with WT Golga7b compared to mutant Golga7b. However, the 
effect size (difference in plasma membrane localised DHHC5) is smaller than that observed for WT 
DHHC5 (Fig 2G), and there is significantly less DHHS5 localised to the plasma membrane compared to 
WT DHHC5 when both are expressed with WT Golga7b (Appendix Figure S5). The fact that any DHHS5 
is localised to the plasma membrane could be due to low levels of palmitoylated Golga7b remaining 
after DHHC5 depletion (Fig 1B) because of residual endogenous DHHC5 activity or compensation by 
other PATs that palmitoylate Golga7b. However, when endogenous DHHC5 is not depleted, the DHHS5 
catalytic mutant when co-expressed with WT Golga7b is localised at the plasma membrane (Figure 
EV3C). This demonstrates that over-expressed Golga7b palmitoylated by endogenous DHHC5 can 
localise the DHHS5 catalytic mutant to the plasma membrane. The localisation of WT DHHC5 co-
expressed with WT Golga7b is unaffected by the presence or depletion of endogenous DHHC5 as 
Golga7b is palmitoylated in both of these conditions (Figure EV3a). 
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Next, we investigated the role of palmitoylation at the C-terminus of DHHC5 and its effect on 
DHHC5 localisation given that the palmitoylation-deficient mutant DHHC5 is unable to interact with 
Golga7b. Unexpectedly, when we co-expressed the DHHC5 C-terminal palmitoylation-deficient 
mutant in DHHC5 depleted cells, with either wild-type or mutant Golga7b (Figure 2E-F) it was localised 
to the plasma membrane. Furthermore, it was localised to the plasma membrane when over-
expressed alone without Golga7b (Figure EV2D). These data suggest that palmitoylation at the C-
terminus of DHHC5 and the potential changes in local protein structure, as a result, may regulate the 
internalisation of DHHC5 from the plasma membrane. 
 
Palmitoylation of Golga7b regulates plasma membrane localisation of endogenous DHHC5 
In order to demonstrate that Golga7b regulates the localisation of endogenous DHHC5, we expressed 
WT or mutant Golga7b in HeLa cells and used immunofluorescence microscopy to probe the 
localisation of endogenous DHHC5 (Figure 3). Expression of WT Golga7b significantly increases levels 
of endogenous DHHC5 at the plasma membrane compared to endogenous DHHC5 without Golga7b 
over-expression (Figure 3A, C and E) indicating that the expression level of Golga7b regulates the 
amount of plasma membrane localised DHHC5. Interestingly, over-expression of mutant Golga7b 
reduces endogenous DHHC5 localisation at the plasma membrane (Figure 3B and F), similar to what 
we observe when both DHHC5 and mutant Golga7b are over-expressed. This indicates that the 
expression of a palmitoylation-deficient form of Golga7b prevents stabilisation of DHHC5 at the 
plasma membrane in a dominant negative manner. 
 In order to more definitively show that over-expressed DHHC5 is mislocalised because of 
insufficient Golga7b levels (Figure EV2B), we depleted Golga7b with siRNA in HeLa cells (Figure 3d). 
We observe that the localisation of endogenous DHHC5 is significantly reduced at the plasma 
membrane upon Golga7b depletion, compared to cells treated with a non-targeting negative control 
siRNA, where DHHC5 was present almost exclusively at the plasma membrane (Figure 3C and D). This 
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confirms that sufficient levels of Golga7b are required to localise DHHC5 to the plasma membrane. To 
ensure this was an effect specific to Golga7b, we attempted to rescue the localisation defect of DHHC5 
due to Golga7b depletion by expression of the closely related Golga7 (GCP16) (Appendix Figure S2). 
Over-expression of Golga7 in Golga7b depleted cells failed to restore DHHC5 to the plasma 
membrane, suggesting that this effect is specific to Golga7b and cannot be significantly rescued by 
related proteins (Appendix Figure S2). 
 
Golga7b defines DHHC5 interactomes  
As Golga7b has such a profound effect on the localisation of DHHC5, we exploited this to investigate 
whether the interactions of DHHC5 are different when it is present at the plasma membrane 
compared to when it is localised to endomembranes. To achieve this, a C-terminal triple FLAG-tagged 
DHHC5 construct was co-expressed with either WT or mutant Golga7b in HeLa cells before performing 
immunoprecipitations. Initially, we sought to prove that DHHC5 would immunoprecipitate proteins 
differentially when present at the plasma membrane or within the cell. We chose Flot2 to test this as 
it is a known DHHC5 substrate [12] and is present at the plasma membrane. DHHC5 is able to 
immunoprecipitate significantly more Flot2 when it is present at the plasma membrane (co-expressed 
with WT Golga7b) compared to when it is present at endomembranes (co-expressed with 
palmitoylation-deficient mutant Golga7b) (Figure 4A). 
In order to explore this more widely, we used an affinity purification-mass spectrometry (AP-
MS) approach in which DHHC5 complexes were purified and competitively eluted by triple-FLAG 
peptide, separated by SDS PAGE, subjected to in-gel digestion and analysed by quantitative tandem 
mass spectrometry. We defined sets of DHHC5 interactors based on their quantitative enrichment in 
IPs versus control (non-transfected) purifications when a) DHHC5 was localised to the plasma 
membrane (co-expressed with WT Golga7b), b) DHHC5 was localised at endomembranes (co-
expressed with palmitoylation-deficient mutant Golga7b), or c) DHHC5 was localised at 
endomembranes and the plasma membrane (expressed alone). In order to rule out any effects of 
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addition of MG132 when we co expressed DHHC5 with palmitoylation-deficient mutant Golga7b, we 
also generated and analysed IPs from cells which we co-expressed DHHC5 with wild-type Golga7b +/- 
MG132. Comparison of enriched proteins in these IPs +/- MG132 identified only one protein 
differentially enriched by the addition of MG132 demonstrating that it did not significantly affect the 
set of DHHC5 interactors. 
Data from these experiments revealed that DHHC5 interacts with many more proteins when 
localised at the plasma membrane by wild-type Golga7b (304 proteins, Figure 4B, Dataset EV1) 
compared to when it is expressed with mutant Golga7b when it is localised to endomembranes (39 
proteins, Dataset EV2), with a small number of proteins common to both conditions (22 proteins) (t-
test with a permutation based FDR 0.05). DHHC5 does interact with a large number of proteins at the 
plasma membrane, however, this is not uncommon for enzymes which may have a large number of 
substrates. We identified several known substrates of DHHC5 including delta-catenin and Flot2 which 
suggests that our AP-MS approach allows the discovery of new substrates of PATs. However, this may 
not be viable in all cases as it is known that some PATs only interact weakly with some of their 
substrates [27]. 
When DHHC5 is expressed alone (Dataset EV3) it interacts with some proteins also identified 
when it was co-expressed with WT Golga7b (52 proteins). Among these are members of the AP2 
complex with is involved in certain types of clathrin-mediated endocytosis and has been shown to be 
involved in endocytosis of DHHC5 [10]. When DHHC5 is expressed alone there are many more 
cytoplasmic proteins identified as interactors compared to when it is co-expressed with WT Golga7b; 
this is likely caused by the mislocalisation of DHHC5 in the absence of exogenous Golga7b. 
 When we directly compare the interaction datasets from DHHC5 co-expressed with WT or 
mutant Golga7b, a number of proteins are differentially enriched; nine were enriched in the 
DHHC5/mutant Golga7b dataset, and 163 in the DHHC5/WT Golga7b dataset (t-test with a 
permutation based FDR 0.05). This clearly demonstrates the profound effect of Golga7b-dependent 
localisation of DHHC5 has on its interactome. To validate this, we chose three proteins that were 
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differently enriched between the WT and mutant Golga7b conditions that were not known as DHHC5 
interactors or substrates. Dsg2, a desmosomal cadherin, Tight junction protein ZO-1 and clathrin heavy 
chain, interacted with DHHC5 significantly more when DHHC5 was at the plasma membrane (co-
expressed with WT Golga7b) compared to when it was at endomembranes (co-expressed with mutant 
Golga7b) (Figures 4D and E), demonstrating that these proteins are bona fide DHHC5 interactors and 
that our AP-MS results are reliable. 
 Among the set of proteins that were significantly enriched when DHHC5 was expressed with 
WT Golga7b compared to mutant Golga7b was a number of proteins associated with clathrin-
mediated endocytosis, including three major members of the AP2 complex (Figure 4C), plus the 
clathrin light and heavy chain. This indicates that the endocytosis of DHHC5 may be mediated by this 
complex, as DHHC5 is known to be actively trafficked away from the plasma membrane in neurons 
[10], and has a number of endocytic sequences in its C-terminal tail. It is likely that DHHC5 interacts 
with the AP2 complex more when it is at the plasma membrane compared to when it is within the cell, 
as the clathrin coat and associated proteins are shed from the endocytic vesicle rapidly after the 
vesicle buds from the membrane [28]. When looking at the proteins that interact with DHHC5 when 
it is co-expressed with WT Golga7b, nine of the top ten over-represented gene ontology terms are 
involved with cell:cell or cell:matrix adhesion (Figure 4G). While it is known that a number of proteins 
involved in adhesion are palmitoylated [20-22], the PATs responsible are mostly unknown. Given the 
large number of proteins immunoprecipitated by DHHC5, particularly in the desmosomal cell adhesion 
complex, we hypothesised that DHHC5 is the PAT responsible for the palmitoylation of these proteins 
and could be a key player in regulating cellular adhesion. In particular, it was noted that the 
desmosomal cadherin Dsg2, which is a known palmitoylated protein [22] and the Tight junction 
protein ZO-1 are both interactors of DHHC5, which opens up the possibility that palmitoylation by 
DHHC5 is an important regulatory process in these two different types of cell adhesion junctions.  
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Palmitoylation of golga7b prevents endocytosis of DHHC5 
As several of the clathrin-mediated endocytosis complex members were found as interactors of 
DHHC5 in our AP-MS study (Figure 4c), we decided to further investigate the mechanism of DHHC5 
internalisation and endocytosis in the context of Golga7b. We first investigated whether it was 
possible to rescue mutant Golga7b-induced mislocalisation of  DHHC5 by inhibiting endocytosis with 
the dynamin inhibitor Dynasore. When HeLa cells expressing WT DHHC5 and mutant Golga7b are 
treated with 25µM Dynasore, the majority of DHHC5 is stabilised at the plasma membrane after a 
relatively short time (within 30 minutes) (Figure 5A, B and E). This shows that DHHC5 is rapidly 
trafficked to and from the plasma membrane in other cell types besides neurons [10]. It also suggests 
a role for Golga7b in stabilising DHHC5 at the plasma membrane by preventing endocytosis.  
As Dynasore may have some off-target effects [29] and does not only target clathrin-mediated 
endocytosis but all types of endocytosis that require dynamin, we confirmed that DHHC5 is trafficked 
by clathrin-mediated endocytosis using siRNA depletion of the AP2µ subunit, which we found as an 
interactor of DHHC5 in the AP-MS experiments. When we depleted AP2µ in HeLa cells co-expressing 
WT DHHC5 and mutant Golga7b, DHHC5 was restored to the plasma membrane, while in cells treated 
with a control non-targeting siRNA DHHC5 remained mislocalised (Figure 5C, D and F). This confirms 
that DHHC5 requires AP2µ for endocytosis from the plasma membrane [10] and that palmitoylation 
of Golga7b prevents endocytosis of DHHC5. Importantly, this demonstrates conclusively that 
palmitoylation deficient Golga7b does not prevent DHHC5 trafficking to or association with, the 
plasma membrane but instead that palmitoylated Golga7b acts by stabilising DHHC5 at the plasma 
membrane.  
As the localisation of DHHC5 can be altered by preventing the palmitoylation of Golga7b or by 
DHHC5 itself (Figure 2), we wanted to directly investigate whether the changes observed were due by 
changes in the endocytosis of DHHC5. A biotin-based endocytosis assay showed that mutant Golga7b 
significantly increases the rate of endocytosis whereas WT Golga7b reduced endocytosis to essentially 
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zero over the 30 minute time course used in the assay (Figure 5G). Furthermore, preventing 
palmitoylation of DHHC5 abolished endocytosis of DHHC5 which bolsters the idea that palmitoylation 
of DHHC5 is essential for the retrieval of DHHC5 from the plasma membrane. This shows that 
palmitoylation of Golga7b and depalmitoylation of DHHC5 both prevent endocytosis of DHHC5.  
 
DHHC5 and Golga7b regulate desmosome trafficking & assembly 
As a number of proteins involved in cell adhesion were found as DHHC5 interactors in our AP-MS study 
(Figure 4C), we wanted to investigate whether any of these proteins were substrates of DHHC5. 
Among these is the important desmosomal cadherin Dsg2 (Figure 4D). Palmitoylation of Dsg2 
regulates its localisation and trafficking to the plasma membrane [23] but the identity of the PAT that 
mediates this is unknown. Because of this, we decided to investigate whether DHHC5 is the PAT 
responsible for Dsg2 palmitoylation by performing ABE assays on DHHC5 depleted and control siRNA 
treated HeLa cells (Figure 6A). We found that upon DHHC5 depletion, Dsg2 palmitoylation is almost 
completely abolished, showing that DHHC5 is the PAT responsible for the majority, if not all, of Dsg2 
palmitoylation. This contradicts previous work which hypothesised that Dsg2 is palmitoylated at the 
Golgi or somewhere within the trafficking pathway [23]. To confirm that DHHC5 palmitoylates Dsg2 
at the plasma membrane, we performed an ABE experiment where A431 cells were cultured in normal 
conditions or in low calcium, where desmosomal components are internalised and no longer at the 
plasma membrane. At low calcium, there was a significant decrease in palmitoylation of Dsg2 which 
is consistent with Dsg2 being palmitoylated at the plasma membrane, where DHHC5 is resident (Figure 
6F). 
 Given that palmitoylation of Dsg2 regulates its localisation to the plasma membrane and its 
trafficking to desmosomes, we investigated the effect of DHHC5 knockdown on the localisation and 
trafficking of Dsg2 using immunofluorescence microscopy of A431 cells with DHHC5 depletion and 
calcium switch assays. In this assay, the calcium dependence of desmosome assembly is exploited; 
cells are cultured in a medium that is free from calcium so that desmosomes are rapidly internalised 
15 
 
and then trafficked back to the plasma membrane when calcium is re-introduced. In A431 cells treated 
with a non-targeting negative control siRNA, Dsg2 returned to the plasma membrane gradually over 
the three-hour time course when calcium was added to the media (Figure 6b, Figure EV4). However, 
when DHHC5 was depleted, Dsg2 signal remained within the cell, with no significant change in the 
level of Dsg2 at the plasma membrane during the three-hour time course (Figure 6C, Figure EV5, 
quantification in Appendix Figure S6). This shows that depletion of DHHC5 significantly inhibits the 
trafficking to or stabilisation of Dsg2 at the plasma membrane. While in our experiments DSG2 was 
never completely depleted from the plasma membrane at low calcium, a significant portion of the 
protein was internalised from the plasma membrane which allowed us to assay the return of DSG2 to 
the plasma membrane over time. This residual plasma membrane signal has been observed in other 
calcium switch studies of DSG2 [30]. 
 In order to establish if Golga7b plays a functional role in desmosome assembly through its 
regulation of DHHC5 localisation, we determined the effect of Golga7b depletion on the localisation 
of Dsg2. As with DHHC5, A431 cells were treated with Golga7b siRNA and a calcium switch assay 
performed. Again, after three hours of calcium being returned to the media, Dsg2 had not returned 
to the plasma membrane at the same level as cells treated with a non-targeting siRNA (Figure 6D). 
This links DHHC5 localisation to the correct trafficking of Dsg2 and implicates Golga7b in the regulation 
of DHHC5 substrates. In order to validate this finding, we performed cell-surface biotinylation 
experiments 3 hours after calcium reintroduction (Figure 6E). This showed very similar results to the 
quantification of the confocal images showing that depletion of DHHC5 leads to a decrease in Dsg2 in 
the plasma membrane. Removal of Golga7b by siRNA also causes a significant drop in Dsg2 at the 
plasma membrane, although to a lesser extent observed with DHHC5 depletion. 
 The Dsg2 localisation phenotype is similar to that seen when palmitoylation of the 
desmosomal protein Pkp3 is prevented [22]. Pkp3 was not found as an interactor of DHHC5, but the 
localisation of Dsg2 after DHHC5 depletion is similar to palmitoylation-deficient Pkp3 mutants [22]. 
We treated HeLa cells with either DHHC5 siRNA or non-targeting control siRNA, performed ABE assays 
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to measure palmitoylation levels of Pkp3 and found that there was a significant and almost total loss 
of palmitoylation of Pkp3 compared to a non-targeting siRNA (Appendix Figure S3). This shows that 
Pkp3 is a DHHC5 substrate and makes it likely that the phenotype seen with Dsg2 localisation and 
trafficking is caused by a combination of the loss of palmitoylation of both Dsg2 and Pkp3. 
 
DHHC5 and Golga7b regulate cell adhesion 
To investigate whether DHHC5 plays a more general role in cell adhesion, or if the localisation and 
palmitoylation defects observed in desmosomes are sufficient to cause a loss of cell adhesion, we used 
a modified form of a cell scatter assay. When cells are exposed to a growth factor they internalise their 
cell:cell and cell:matrix adhesion proteins which cause cells to scatter away from the colonies they 
naturally form and mimics the epithelial to mesenchymal transition. All cell adhesion proteins are 
targeted in this assay, but a deficiency in one of more aspects of the adhesion machinery will lead to 
a change in scattering. The speed and distance of this scattering are dependent on cell adhesion, with 
reduced adhesion leading to enhanced cell scattering [31]. When A431 cells were subject to DHHC5 
depletion before treatment with low levels of EGF (5ng/ml), cells scattered noticeably (Figure 7B and 
C), whereas control non-targeting siRNA treated cells remained in colonies when treated with the 
same concentration of EGF (Figure 7A and C). This shows that depletion of DHHC5 leads to a reduction 
of adhesion of cells to one another and implicates DHHC5 in a wider role in cell:cell adhesion. 
However, it must also be noted that this increase in scattering could also be caused by the inhibition 
of cell:matrix adhesion as well as cell:cell adhesion.  
To test if depletion of Golga7b mirrors the effects seen with DHHC5 depletion in the calcium 
switch assay, we performed cell scatter assays on Golga7b depleted A431 cells (Figure 7D E and F). We 
observed enhanced scattering of cells upon Golga7b depletion compared to control cells exposed to 
a non-targeting siRNA. This shows Golga7b has a functional role in cell adhesion which is likely to be 
caused by its regulation of DHHC5 localisation. Given that we have shown that DHHC5 interacts not 
only with Dsg2 but also with Tight junction protein ZO-1 (Dataset EV2, Figure 4F), it is possible that the 
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wider effects that DHHC5 depletion has on cell adhesion could be caused by disruption of both 
desmosomes and tight junctions. 
 To further demonstrate a functional role of DHHC5 and Golga7b in cell adhesion, we 
performed trans-epithelial electrical resistance assays (TEER). This involves the growth of cells on a 
semi-permeable membrane support and measurement of the electrical resistance across this 
membrane; the stronger the cell adhesion, the higher the resistance measurement will be [32]. When 
we performed this assay on confluent A431 cells that were treated with either DHHC5 or negative 
control non-targeting siRNA, we observed a significant reduction in electrical resistance in cell cultures 
treated with DHHC5 or Golga7b siRNA (Figure 7G). This shows that the adhesion between the cells is 
reduced in these conditions highlighting that the DHHC5/Golga7b complex is an important regulator 
of the cell adhesion machinery. Given that cell:cell adhesion is measured in TEER assays, this finding 
supports the idea that  that the changes observed in the cell scatter assays were due to changes in the 
cell:cell rather than cell:matrix adhesion machinery. 
 
DISCUSSION 
The regulation of subcellular localisation of many PATs is poorly understood, and DHHC5 is unique 
among them as it is the only known PAT to exhibit dynamic changes in localisation in response to 
external stimuli [10]. While it has been shown in neurons that the localisation of DHHC5 is regulated 
by phosphorylation, we have shown that the localisation of DHHC5 is also regulated by the interaction 
and palmitoylation of an accessory protein, Golga7b. It is notable that the over-expression of 
palmitoylation-deficient mutant Golga7b causes mislocalisation of endogenous DHHC5 which 
suggests that Golga7b has a dominant negative effect on DHHC5. Over-expression of WT Golga7b 
increases localisation of endogenous DHHC5 at the plasma membrane, which further strengthens the 
argument that the level of Golga7b within the cell is an important determinant of DHHC5 localisation. 
The catalytically dead DHHC5 (DHHS5) mutant localises to the plasma membrane when co-expressed 
with Golga7b in the presence of endogenous DHHC5, but this localisation is significantly reduced in 
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cells depleted of endogenous DHHC5. This shows that DHHC5 mediated palmitoylation of Golga7b is 
required for stabilisation of DHHC5 at the plasma membrane. 
 Palmitoylation of sites in the C-terminus of DHHC5 is required for its interaction with Golga7b 
and stabilisation at the plasma membrane and mutation of these sites prevents its internalisation 
(Figure 8). Sorting signals in the C-terminal tails of PATs are important factors in controlling their 
localisation and are able to switch the localisation of a PAT from the Golgi to the ER [33]. Our results 
suggest that palmitoylation of DHHC5 is not required for correct trafficking of DHHC5 to the plasma 
membrane nor for the interaction between DHHC5 and the endocytic machinery, as the known 
endocytic interaction motifs are unaffected by these mutations [10]. The data presented here suggest 
that when palmitoylated DHHC5 is not bound to Golga7b, it is endocytosed. Preventing palmitoylation 
of the GluR1 subunit of the AMPA receptor inhibits its endocytosis [34], which is similar to what we 
propose for DHHC5. Interestingly, the three palmitoylation sites on the C-terminal tail of DHHC5 map 
to an amphipathic alpha helix in the corresponding crystal structure of DHHC20 [35] and this 
palmitoylation could potentially pin this helix to the plasma membrane thereby altering the 
conformation of the C-terminal tail. As the majority of DHHC5 is palmitoylated on two or more sites 
in vivo [9], it suggests that palmitoylation could play a major role in the regulation of cell surface 
expression of DHHC5.  
The observation that DHHC5 requires interaction with Golga7b for stabilisation at the plasma 
membrane appears to be in conflict with the finding that C-terminal DHHC5 mutant, which does not 
interact with Golga7b, is stabilised at the plasma membrane. The DHHC5 C-terminal mutant, while 
being unable to interact with Golga7b, is unable to be internalised because it is not palmitoylated on 
its C-terminus. This raises the possibility that the interaction with Golga7b functions to protect C-
terminally palmitoylated DHHC5 from endocytosis and suggests that palmitoylation of the C-terminal 
tail of DHHC5 is an endocytic trigger for the protein (Figure 8). 
Activity-dependent trafficking of DHHC5 has been described to occur in neurons after long-
term potentiation [10]. Here, we have confirmed that DHHC5 is endocytosed from the plasma 
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membrane by the AP2-regulated clathrin mediated endocytosis pathway in HeLa cells. Interestingly, 
the results presented here suggest that DHHC5 is trafficked as part of its normal lifecycle and does not 
require stimulation of cells in any way, as DHHC5 is restored to the plasma membrane within 30 
minutes of Dynasore treatment (Figure 5). This could be a general feature of DHHC5 in all cell types or 
it could have different cycling dynamics in various specialised cell types. Importantly, inhibition of 
endocytosis corrects the localisation defect when DHHC5 is co-expressed with mutant Golga7b. This 
demonstrates that the palmitoylation deficient Golga7b does not prevent trafficking of DHHC5 to the 
plasma membrane. Instead, Golga7b acts to stabilise DHHC5 at the plasma membrane by preventing 
its internalisation.  
 Our unbiased AP-MS experiments uncovered a new role for DHHC5 in cell adhesion. 
Palmitoylation regulates several proteins involved in cell:cell and cell:matrix adhesion [19-22] and for 
many of them, palmitoylation regulates their localisation. Among cell adhesion complexes, 
desmosomes are notable for the number of proteins in the complex that are palmitoylated, with at 
least 6 members of the complex palmitoylated in A431 cells [22]. In this work, we have shown that 
DHHC5 is the PAT responsible for the palmitoylation of the key complex members Dsg2 and Pkp3. We 
have also demonstrated that knockdown of DHHC5 affects the trafficking and localisation of Dsg2, 
which had been demonstrated previously to be dependent on Dsg2 palmitoylation, albeit with a 
noticeably milder phenotype than we observed [23]. It is also notable that the knockdown of Golga7b 
also caused defects in Dsg2 localisation and trafficking demonstrating a functional role for Golga7b in 
cell adhesion. Our data imply that plasma membrane localisation of DHHC5 is required for efficient 
Dsg2 palmitoylation and either trafficking or incorporation into desmosomes, or possibly both of these 
processes. However, these results contradict previous work which suggested that palmitoylation of 
Dsg2 occurs at the Golgi which facilitates trafficking to the plasma membrane [23].  The reasons for 
this apparent contradiction are unclear, but the same study showed that palmitoylation-deficient Dsg2 
is still able to reach the plasma membrane. This indicates that palmitoylation of Dsg2 is not strictly 
required for trafficking to the plasma membrane and that once Dsg2 reaches the plasma membrane 
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it is palmitoylated by DHHC5 which facilitates its incorporation and therefore stabilisation in 
desmosomal complexes. However, DHHC5 appears to cycle between the plasma membrane and 
endomembranes, making is possible that Dsg2 is palmitoylated by DHHC5 at non plasma membrane 
ƐŝƚĞƐ ?ƐŝŵŝůĂƌƚŽǁŚĂƚŚĂƐďĞĞŶĚĞŵŽŶƐƚƌĂƚĞĚĨŽƌɷ-catenin at dendritic spines [10]. This is a less likely 
scenario, however, when we consider our data from low calcium conditions, which cause Dsg2 to be 
localised away from the plasma membrane and therefore away from DHHC5, leading to a significant 
reduction in palmitoylation of Dsg2.  
Furthermore, we have determined that Pkp3 is also a DHHC5 substrate and as it has been 
shown previously that palmitoylation of Pkp3 regulates the localisation of Dsg2 as well as a number of 
other desmosomal components [22]; this would indicate that DHHC5 regulates the localisation and 
assembly of desmosomes more generally. The finding that Pkp3 is a DHHC5 substrate also helps to 
explain why the localisation and trafficking phenotype of Dsg2 upon DHHC5 knockdown is more severe 
than when Dsg2 palmitoylation alone is prevented. Loss of Pkp3 palmitoylation has a profound effect 
on the localisation of Dsg2 [23]. These findings reveal a completely novel role for DHHC5 in the 
regulation of desmosome function. 
We established a broader role for DHHC5 in cell adhesion by observing increased scattering 
of DHHC5 depleted cells due to a reduction in cell adhesion. To our knowledge, this is the first report 
of a specific PAT that regulates the palmitoylation of essential adhesion proteins and that its depletion 
leads to defects in cell adhesion. The link between DHHC5 and adhesion is not without precedent, 
however, as a number of known DHHC5 substrates have roles in cell adhesion. Flot2 regulates the 
stability of DSG3 at the plasma membrane and depletion of Flot2 leads to reduced desmosomal 
adhesion [36]. As DHHC5 can palmitoylate Flot2 palmitoylation [12], it is possible that DHHC5 could 
have a role in desmosomal adhesion through this pathway in addition to palmitoylation of Pkp3 and 
Dsg2 as demonstrated in this work. However, palmitoylation of Flot2 was not completely lost upon 
depletion of DHHC5 in our experiments, our data from PEG switch assays suggest that Flot2 is still 
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palmitoylated at one to two sites (Appendix Figure S4). This is in contrast to the complete loss (below 
limit of detection) of palmitoylation of Dsg2 and Pkp3. 
ŶŽƚŚĞƌ,, ? ƐƵďƐƚƌĂƚĞɷ-catenin competes with p120ctn to interact with the adhesion 
protein E-cadherin [37] ?ɷ-catenin binding to E-cadherin reduces p120ctn at cell junctions and inhibits 
adhesion and E-cadherin binds to desmogleins 2 and 3 to promote desmosome formation [38]. This 
suggests that DHHC5 could influence the assembly, stability and location of desmosomes through a 
number of mechanisms, and this work shows that it has a direct regulatory role for at least two 
members of the demosomal protein complex. 
The regulation of cell adhesion by DHHC5 has some potentially interesting implications for 
DHHC5 in disease. Disruption of desmosomes in the heart is known to lead to the serious heart 
condition arrhythmogenic right ventricular cardiomyopathy (ARVC) [39].  To the best of our 
knowledge, palmitoylation of desmosomal proteins has not been implicated in ARVC to date, but given 
that DHHC5 has been shown to be enriched in the heart [2], it is possible that palmitoylation of 
desmosomal proteins by DHHC5 in the heart could play a role in this condition. It also opens up the 
possibility of DHHC5 being used as a marker for potential cancer metastasis, as the results presented 
here suggest that a lower level of DHHC5 in a cell would lead to an increased chance of metastasis due 
to reduced cell adhesion.  
 In conclusion, the results presented in this work establish a new mechanism of DHHC5 
localisation through the action of Golga7b and implicate DHHC5 and Golga7b as important members 
of cellular adhesion machinery. Going forward, the exact molecular mechanism of how Golga7b 
influences DHHC5 localisation and how their interaction is mediated will be important questions to 
address to fully understand this novel regulatory mechanism. It will also be important to investigate 
the triggers that control the endocytosis of DHHC5 and how palmitoylation and phosphorylation of 
DHHC5 work in concert to control its presence at the plasma membrane.  
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MATERIALS AND METHODS 
Cell culture 
All cells were grown in normal DMEM (Gibco) supplemented with 1% penicillin/sptreptomycin (Gibco), 
except for during Calcium switch experiments, when A431 cells were grown in calcium free DMEM 
(Gibco). All transfection was carried out using polyethylinimine (PEI, 25kDa linear, Alfa Aesar) using a 
ratio of 1:3 of DNA:PEI with cells allowed to grow for 24 hours after transfection before harvesting or 
fixing unless otherwise stated. For siRNA treatments, siRNA was mixed with mission siRNA transfection 
siRNA transfection reagent (Sigma Aldrich) and incubated for 30 minutes at room temperature before 
the mixture was added to cells. SiRNA used: DHHC5, Golga7b, AP2µ, universal non-targeting control 
(All Dharmacon, SMARTPool) 
Constructs 
N-terminally HA-tagged DHHC5 construct was a kind gift from Dr Andrew Peden. All other contructs 
were ordered from Genscript with either human DHHC5 (GeneID 25921) or human Golga7b (GeneID 
401647) as templates. All ORF clones were under the CMV promoter in the pcDNA3.1+ vector which 
had either a FLAG or HA tag following the protein coding region before the stop codon. SiRNA was 
obtained from Dharmafect. Cysteine residues mutated in the Golga7b constructs were at positions 33, 
78, 81, 90 and 141. DHHC5 residues mutated were at position 134 for catalytic mutant and positions 
236, 237 and 245 for C-terminal mutant. 
Antibodies 
Anti-DHHC5 (Atlas Antibodies), for ICC 1:250, for immunoblotting 1:1000. Anti-Golga7b (Bioss 
Antibodies), for ICC 1:100, for immunoblotting 1:1000. Anti-FLAG (Sigma Aldrich), for ICC 1:500, for 
immunoblotting 1:1000. Anti-HA (Sigma Aldrich), for ICC 1:200. Anti-AP2µ (Genetex), for ICC 1:150, 
for immunoblotting 1:1000. Anti-Dsg2 (Santa Cruz Biotech), for ICC 1:200, for immunoblotting 1:250. 
Anti-Pkp3 (Santa Cruz Biotech), for immunoblotting 1:200. Anti-Flot2 (Cell Signalling Technology), for 
immunoblotting 1:1000. Anti-Actin (Cell Signalling Technology), for immunoblotting 1:2500. Anti-
Rabbit HRP (Thermo Fisher Scientific), for immunoblotting 1:2500. Anti-Mouse HRP (Cell Signalling 
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Technology), for immunoblotting 1:2500. Anti-Mouse Alexa Fluor 488 (Invitrogen), for ICC 1:2500. 
Anti-Rabbit Alexa Fluor 594 (Invitrogen), for ICC 1:2500. Anti-Chicken Alexa Fluor 647 (Invitrogen), for 
ICC 1:2500. 
Acyl-Biotin Exchange 
Cell pellets were collected and resuspended in lysis buffer (2.5% sds, 50mM Tris pH 7.2, 50mM NaCl, 
1mM EDTA) and then homogenised using an electric homogeniser for 15 seconds. Lysates were heated 
at 70°C for 15 minutes before being centrifuged at 16,000xg for 10 minutes and the supernatants 
retained. After cooling, maleimide (Sigma Aldrich) was added to 100mM final concentration and 
incubated for 3 hours at 40°C with shaking. Samples were then acetone precipitated by the addition 
of 4x volume of -20°C acetone and resuspended twice in lysis buffer with 5 washes with ice cold 
acetone after each precipitation to remove any excess maleimide. Lysates were split into + and  
hydroxylamine (HA) treatment conditions. The +HA samples had 2M hydroxylamine/50mM Tris pH 7.4 
added to a final hydroxylamine concentration of 1M, while the HA samples had an equal volume of 
50mM Tris pH 7.4 added. HA was made fresh immediately before use and prepared by dissolving 
hydroxylamine in distilled water before the pH was adjusted up to 7.4 with NaOH. EZ link Biotin-HPDP 
(Thermo Fisher) dissolved in DMSO, mixed with N,N-dimethylformamide and then added to samples 
at a final concentration of 0.5mM. Samples were then incubated for 1 hour at 37°C with shaking. 
Proteins were precipitated with acetone and then washed 4 times with ice cold acetone to remove 
any excess biotin. Protein was resuspended in IP buffer (1% triton x-100, 50mM tris pH 7.2, 150mM 
NaCl, 1mM EDTA, protease inhibitor cocktail 1:200 (Sigma)) and incubated with 30µl of streptavidin-
sepharose resin (Thermo Fisher), which was prewashed twice with IP buffer, for 1 hour at room 
temperature with end-over-end rotation. The resin was washed 4 times in the IPbuffer before elution 
of bound proteins by the addition of 20mM TCEP for 20 minutes at 37°C with shaking. Eluted proteins 
were collected by centrifugation at 800xg for 5 minutes and the supernatants were retained. Samples 
were stored at -20°C until further use. 
Immunoprecipitation 
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Cell pellets were collected and immediately resuspended in lysis buffer (1% triton x-100, 50mM tris 
pH 7.2, 150mM NaCl, 1mM EDTA, protease inhibitor cocktail 1:200 (Sigma)). Samples were then 
rotated end-over-end at 4°c for 30 minutes before spinning at 16,000xg for 5 mins. The supernatants 
were retained. 100µl of anti-FLAG M2 resin (Sigma Aldrich  A2220) was washed in lysis buffer without 
protease inhibitors 3 times, added to the samples and then left overnight with end-over-end rotation 
at 4°c. Samples were then spun at 800xg for 2 minutes to collect the resin before being washed 5 times 
for 5 minutes each at room temperature with end-over-end rotation with lysis buffer without protease 
inhibitors. Immunoprecipitated proteins were eluted by 3 times resin bed volume of 2mg/ml triple 
FLAG peptide (Sigma Aldrich) dissolved in lysis buffer without protease inhibitors for 30 mins at room 
temperature with end over end rotation. The samples were then centrifuged at 800xg for 5 minutes 
and the supernatants retained. Eluted proteins were stored at -20°C until further use. For 
immunoprecipitations of endogenous proteins from mouse forebrain, a whole mouse forebrain was 
added to a lysis buffer (1% triton x-100, 1% sodium deoxycholate, 50mM tris pH 7.2, 150mM NaCl, 
1mM EDTA, protease inhibitor cocktail 1:200 (Sigma)) and homogenised 10 times with a dounce 
homogeniser on ice. Samples were spun at 16,000xg and the supernatant retained as above. Samples 
were pre-cleared with protein G sepharose before centrifugation and retention of the supernatant. 
Samples were then incubated with either anti-DHHC5 or anti-Golga7b antibodies and protein G 
sepharose overnight at 4°C. The resin was then washed 5 times with lysis buffer before elution of 
bound proteins by heating the resin for 20 minutes at 70°C. 
Immunocytochemistry 
Cells were seeded onto glass coverslips in a 12 well plate and were grown for 24 hours. The media was 
changed and cells were transfected with a 3:1 ratio of PEI:cDNA for 24 hours as described previously. 
Media was removed, coverslips were washed briefly with 1-2 ml of PBS and cells were fixed with 4% 
PFA for 10 minutes at room temperature. Cover slips were washed again with PBS before 
permeabilisation with 0.3% triton x-100-PBS (vol/vol) for 15 minutes at room temperature with gentle 
agitation. After washing with PBS, coverslips were blocked with 0.2% fish skin gelatin (Sigma 
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Aldrich)/0.01% triton x-100 (vol/vol) in PBS (blocking solution) for an hour at room temperature with 
agitation. Primary antibody was incubated at the concentrations mentioned previously diluted in 
blocking solution for 1 hour at room temperature. Coverslips were washed three times for 5 minutes 
with 1ml of PBS with gentle agitation before incubation with secondary antibodies diluted in blocking 
solution for 2 hours at room temperature, protected from light by wrapping plates in tin foil with 
gentle agitation. Coverslips were then washed with 1ml of PBS 3 times for 5 minutes with gentle 
agitation before mounting on glass slides with DAPI fluoromount-G mounting media (Southern 
Biotech) before being kept in dark at 4°C before confocal imaging. 
 
 
Calcium switch assaysA431 cells were seeded on glass coverslips in a 12 well plate with either normal 
DMEM or low Calcium (5µM calcium) DMEM and placed back into the incubator for 18 hours. Control 
or targeted siRNA was then added as described previously and cells were placed back into the 
ŝŶĐƵďĂƚŽƌĨŽƌ ? ?ŚŽƵƌƐ ?ĂůA?ǁĂƐƚŚĞŶĂĚĚĞĚƚŽƚŚĞ ůŽǁĐĂůĐŝƵŵŵĞĚŝĂƚŽĂĨŝŶĂůĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨ
2mM for 30 minutes, 1 or 3 hours. Control cells were left in low calcium media. Cells were then fixed 
with 4% PFA and prepared as described previously in the immunocytochemistry section. 
Confocal Microscopy 
All confocal microscopy was performed on a Nikon A1 confocal microscope using the following laser 
wavelengths: 405nm (blue), 488nm (green), 561nm (red) and 640nm (far-red). Images were acquired 
using a 60x objective lens and the NIS elements program (Nikon instruments) in an ND2 format. For 
all samples, no primary and no secondary controls were used to threshold the exposure at each 
individual laser wavelength. All images were analysed using the FIJI [40] and imageJ [41] software 
packages. To assess plasma membrane or internal protein signal, the colour channels were split to 
isolate the channel of interest. The free draw tool was used to draw around a single cell and the mean 
intensity, raw integrated density and integrated density were measured. The shape was then moved 
just within the plasma membrane of the cell and the same measurements recorded. The ratio of the 
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two means was then used to calculate the level of protein signal at the plasma membrane (higher 
ratio indicates more signal at the plasma membrane). In calcium switch assays, the remaining DSG2 
signal at the plasma membrane was used to identify the plasma membrane for image quantification 
purposes. 
Immunoblotting 
Samples were run on 10% tris-glycine acrylamide gels unless otherwise stated and proteins were 
transferred to 0.2µm polyvinylidene difluoride membranes (Thermo Fisher) for 90 minutes at 30V 
Membranes were blocked for 1 hour at room temperature on a roller in pbs 0.1%-tween-20 (vol/vol, 
pbs-t) 5% skim milk powder (weight/vol), before overnight incubation with primary antibody diluted 
in pbs-t 1% skim milk powder (weight/vol) at 4°C on a roller. Membranes were then washed 5 times 
with 10 ml pbs-t for 5 minutes each on a roller at room temperature, before incubation with secondary 
antibody diluted in pbs-t 1% milk for 1 hour at room temperature. Membranes were washed again 5 
times with 10ml pbs-t for 5 minutes before a final wash with 10ml pbs. Clarity ECL solution (Bio-Rad) 
was added in a 1:1 ratio of peroxide solution:luminol/enhancer solution with a final volume of 10ml 
for 5 minutes at room temperature on a roller before another wash with pbs on a roller at room 
temperature. Blots were imaged by exposure on CL-X posure x-ray film (Thermo Fisher) prior to 
development to visualise protein bands. 
Mass spectrometry 
In-gel digestion was performed as reported previously [42]. Extracted peptides were re-suspended in 
0.5% formic acid and analysed by nanoflow LC-MS/MS using an Orbitrap Elite (Thermo Fisher) hybrid 
mass spectrometer equipped with a nanospray source, coupled to an Ultimate RSLCnano LC System 
(Dionex). The system was controlled by Xcalibur 2.1 (Thermo Fisher) and DCMSLink 2.08 (Dionex). 
Peptides were desalted on-line using a micro-Precolumn cartridge (C18 Pepmap 100, LC Packings) and 
then separated using a 130 minute gradient from 3%-40% buffer B (0.5% formic acid in 80% 
acetonitrile)  on an EASY-^ƉƌĂǇĐŽůƵŵŶ ? ? ?രĐŵരA?ര ? ?രA?ŵ/ ?WĞƉDĂƉ ? ? ? ?രA?ŵƉĂƌƚŝĐůĞƐ ? ? ? ?രƉŽƌĞ
size (Thermo). The LTQ-Orbitrap Elite was operated with a cycle of one MS (in the Orbitrap) acquired 
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at a resolution of 60,000 at m/z 400, with the top 20 most abundant multiply-ĐŚĂƌŐĞĚ ? ?രA?രĂŶĚŚŝŐŚĞƌ ?
ions in a given chromatographic window subjected to MS/MS fragmentation in the linear ion trap. An 
FTMS target value of 1e6 and an ion trap MSn target value of 1e4 was used and with the lock mass 
(445.12002 ? ?ĞŶĂďůĞĚ ?DĂǆŝŵƵŵ&dD^ƐĐĂŶĂĐĐƵŵƵůĂƚŝŽŶƚŝŵĞŽĨ ? ? ?രŵƐĂŶĚŵĂǆŝŵƵŵŝŽŶƚƌĂƉD^Ŷ
ƐĐĂŶĂĐĐƵŵƵůĂƚŝŽŶƚŝŵĞŽĨ ? ? ?രŵƐǁĞƌĞƵƐĞĚ ?ǇŶĂŵŝĐĞǆĐůƵƐŝŽŶǁĂƐĞŶĂďůĞĚǁŝƚŚĂƌĞƉĞĂƚĚƵƌĂƚŝŽŶ
ŽĨ ? ?രƐǁŝƚŚĂŶĞǆĐůƵƐŝŽŶůŝƐƚŽĨ ? ? ?ĂŶĚĂŶĞǆĐůƵƐŝŽŶĚƵƌĂƚŝŽŶŽĨ ? ?രƐ ?
Mass spectrometry data analysis 
All raw mass spectrometry data were analysed with MaxQuant version 1.5.6 [43]. Data were searched 
against a human UniProt sequence databases (downloaded June 2015) using following search 
parameters: digestion set to Trypsin/P, methionine oxidation and N-terminal protein acetylation as 
variable modifications, cysteine carbamidomethylation as a fixed modification, match between runs 
was enabled with a match time window of 0.7 minutes and a 20 minute alignment time window, label 
free quantification was enabled with a minimum ratio count of 2, minimum number of neighbours of 
3 and an average number of neighbours of 6. PSM and protein match thresholds were set at 0.1ppm. 
A protein FDR of 0.01 and a peptide FDR of 0.01 was used for identification level cut offs. For 
immunoprecipitation data, protein groups file generated by MaxQuant were loaded into the Perseus 
platform [44] with the LFQ intensity from each individual run as main columns. The matrix was filtered 
to remove all proteins that were potential contaminants, only identified by site and reverse 
sequences. The LFQ intensities were then transformed by log2(x) and individual LFQ columns were 
grouped by experiment (e.g. all control experiments grouped, all DHHC5 pulldowns grouped etc.). 
Rows without valid values in 3 out of 4 runs in at least one of the groups were removed and all 
remaining missing values were replaced from the normal distribution with each column imputed 
individually. Following this, a two-tailed Students T-test with S0 set to 3 and a permutation based FDR 
of 0.05 was performed and all non-significant proteins were removed and the matrix was exported in 
a .txt format for further analysis. For further filtering of results, files analysed using the online 
Contaminant Repository for Affinity Purification Mass Spectrometry Data program  [45] with 
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additional controls (CC130, CC135, CC136, CC137). Proteins with an SP score above 0.95 were 
considered bona fide interactors. Gene ontology analysis was performed using the WebGestalt 
platform [46] with the following parameters: species set to homo sapiens, reference gene set was 
genome protein coding, FDR set to 0.01 with Benjani Hochberg multiple test adjustment. 
Cell Scatter Assay 
10,000 A431 cells were seeded in single wells of 6 well plates 24 hours after treatment with either 
DHHC5 or non-targeting siRNA. Cells were grown for 24 hours before media was removed and 
replaced with serum free DMEM and cells were incubated for 8 hours. Cells were imaged at 10x 
magnification on a Nikon Widefield microscope system, positions of fields of view recorded, EGF was 
added to a final concentration of 5ng/ml and cells were incubated for 48 hours. Cells were then imaged 
again at the same positions as previously. To quantify scattering, the grid tool of ImageJ was used, 
with the number of grid squares occupied by cells compared at 0 and 48 hours. 
Trans-epithelial electrical resistance 
125,000 A431 cells were seeded in transwell inserts in 24 well plates which had a 0.4µm pore size. 
Cells were allowed to grow for 12 hours until confluency before treatment with siRNA, which was 
performed for 24 hours. The resistance in each well was measured 3 times with an epithelial 
voltohmmeter. The measurements for each well were averaged and a blank value of a transwell insert 
without cells was subtracted from each measurement before statistical analysis. 
Cell surface biotinylation 
The procedure was performed essentially as described previously [10]. In brief, cells were was with 
PBS supplemented with 0.1mM Magnesium chloride and 1mM Calcium chloride (PBS-CM), before 
treatment for 30 minutes at 4°C with PBS-CM with 1mg/ml NHS-SS-Biotin (Thermo). Cells were then 
washed with PBS-CM, then twice with PBS-CM with 50mM glycine at 4°C. Cells were then lysed in a 
buffer containing 50mM Tris pH 7.2, 1mM EDTA, 1% IGEPAL CA-630 and protease inhibitors (1:200, 
Sigma). Lysates were then incubated with Streptavidin agarose resin (Sigma) over night at 4°C with 
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agitation. The resin was then washed 5 times in lysis buffer supplemented with 150mM NaCl before 
lysis with PAGE buffer with 50mM TCEP at 70°C. 
Endocytosis assay 
The method was performed as previously described [47] with some minor changes. In short, cells were 
washed with PBS-CM twice for 15 minutes at 4°C before the addition of PBS-CM supplemented with 
1mg/ml NHS-SS-Biotin for 30 minutes at 4°C. Cells were then moved back to 37°C while being washed 
3 times with PBS-CM for 5 minutes each. Cells were then treated 4 times with glutathione buffer 
(75mM NaCl, 1mM MgCl2, 0.1mM CaCl2, 50mM GSH, 80mM NaOH and 10% FBS) at 4°C. Cells were 
then lysed and a pull-down performed with streptavidin agarose exactly as described for the cell 
surface biotinylation assay. 
PEG switch 
PEG switch assay was performed essentially as described previously [48]. In short, cells were lysed 
with in lysis buffer containing 2.5% SDS, 1mM EDTA and 50mM tris pH 7.2. Lysates were heated at 
70°c for 20 minutes and DNA was sheared by passing the lysates through a fine gauge needle. After 
cooling, HEPES buffer and maleimide were both added to 100mM final concentration and samples 
were incubated at 40°c for 3 hours with shaking to block all free cysteines. Protein was precipitated 
with a 4x volume of ice-cold acetone, and the pellet was washed 5 times with 80% acetone to remove 
any excess maleimide. Pellets were resuspended in 1% SDS, 1mM EDTA and 50mM Tris pH 7.2 and 
split into +/- hydroxylamine samples. To the +HA sample 2M HA pH 7.2/50mM tris pH 7.2 was added 
to a final concentration of 1M HA, to the HA sample, the same volume of 50mM tris pH 7.2 was 
added. Samples were left at room temperature for 1 hour with end over end rotation. Acetone 
precipitation of protein was performed as described above. Pellets were resuspended in 1% 
SDS/50mM tris pH 7.2, and mPEG 5kDa was added to 5mM final concentration. Samples were 
incubated at 25°c for 1 hour with shaking. Protein was acetone precipitated as described above. Pellets 
were resuspended in 2.5% SDS/50mM tris, before Western Blotting. 
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Data Availability  
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE (https://www.ebi.ac.uk/pride/archive/) (Martens et al, 2005) partner repository with 
the dataset identifier PXD011553. 
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FIGURE LEGENDS 
Figure 1: A palmitoylation-dependent interaction between DHHC5 and Golga7b.  
(A) Immunoblots of acyl-biotin exchange purifications from Hela cells transiently transfected with WT 
Golga7b or a palmitoylation-deficient mutant form of the protein with cysteines replaced with alanine 
residues. The hydroxylamine sensitivity of the Golga7b signal in the + HA condition of the WT pull-
down and not in either the  HA condition or the + HA condition of the mutant shows that Golga7b is 
a palmitoylated protein.  
(B) Immunoblots of acyl-biotin exchange purifications from Hela cells treated with either DHHC5 siRNA 
or control non-targeting siRNA.  
(C) Immunoblots showing rescue of Golga7b palmitoylation in DHHC5 depleted cells after transfection 
of WT DHHC5 but not by the DHHC5 catalytic mutant.  
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(D) A significant reduction in the Golga7b signal is observed in the + HA condition of the pull-down 
when DHHC5 is depleted with siRNA. The graph displays mean +/- s.e.m. N=4, *=p<0.05, paired t-test.  
(E) Immunoblots of WT and non-palmitoylatable mutant Golga7b from immunoprecipitations of WT 
DHHC5 and a pair of DHHC5 mutants (DHHS5 = catalytically inactive mutant where catalytic cysteine 
has been mutated to serine, C-terminal mutant = mutant where the 3 C-terminal palmitoylation sites 
of DHHC5 have been mutated to alanine residues.). WT and DHHS5 immunoprecipitates both WT and 
mutant Golga7b but the C-terminal mutant is unable to immunoprecipitate either form of Golga7b 
showing that the palmitoylation of the C-terminus of DHHC5 is essential for the stability of this 
interaction.  
 
Figure 2: Regulation of DHHC5 localisation by palmitoylation of Golga7b and the C-terminus of 
DHHC5.  
Tagged constructs with palmitoylation site mutations in DHHC5 and Golga7b were expressed in in 
HeLa cells depleted of endogenous DHHC5.  
( A) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and DHHC5 (2nd column), 
with a merged image (3rd column).  
(B) Confocal images of HeLa cells co-expressing palmitoylation deficient mutant Golga7b (1st column) 
and DHHC5 (2nd column), with a merged image (3rd column).  
(C) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and the catalytic mutant 
DHHS5 (2nd column), with a merged image (3rd column).  
(D) Confocal images of HeLa cells co-expressing palmitoylation deficient mutant Golga7b (1st column) 
and DHHS5 (2nd column), with a merged image (3rd column).  
(E) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and DHHC5 C-terminal 
palmitoylation deficient mutant (2nd column), with a merged image (3rd column).  
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(F) Confocal images of HeLa cells co-expressing palmitoylation deficient mutant  Golga7b (1st column) 
and DHHC5 C-terminal palmitoylation deficient mutant (2nd column), with a merged image (3rd 
column).  
(G) Quantification of the plasma membrane signal of DHHC5 in each of the images (A-F), the graph 
displays mean +/- s.e.m.  ****=p<0.001, n.s. = not significant, unpaired t-test. N=35, DHHC5 + WT 
Golga7b. N=41, DHHC5 + mutant Golga7b. N=35, DHHS5 + WT Golga7b. N=31, DHHS5 + Golga7b 
mutant. N=29, C-terminal mutant + WT Golga7b. N=30, C-terminal mutant + mutant Golga7b. Co 
expression of palmitoylation-deficient mutant Golga7b significantly reduces DHHC5 as well as DHHCS5 
signal at the plasma membrane. The majority of the DHHC5 C-terminal palmitoylation-deficient 
mutant is localised to the plasma membrane in a Golga7b independent manner. All N numbers refer 
to the number of cells imaged and quantified, all experiments repeated 4 times.  
Data information: All images show ectopic protein expression only. All scale bars 10µm. 
 
Figure 3: Palmitoylated Golga7b stabilises endogenous DHHC5 at the plasma membrane.  
(A) Confocal images of endogenous DHHC5 in HeLa cells expressing FLAG-tagged WT Golga7b.  
(B) Confocal images of endogenous DHHC5 in HeLa cells expressing FLAG-tagged mutant Golga7b.  
(C) Confocal images of endogenous Golga7b and DHHC5 in HeLa cells treated with negative control 
non-targeting siRNA.  
(D) Confocal images of endogenous Golga7b and DHHC5 in HeLa cell treated with Golga7b siRNA.  
(E) Quantification of plasma membrane signal of endogenous DHHC5 when co-expressed with WT or 
mutant Golga7b or without any transfected Golga7b. ****=P<0.001, t-test, endogenous + WT Golga7b 
n=37, endogenous + mutant Golga7b n=23, endogenous n=42. Expression of the palmitoylation 
deficient mutant Golga7b causes endogenous DHHC5 to be internalised in the cell, while WT Golga7b 
stabilises DHHC5 at the plasma membrane. 
(F) Quantification of the plasma membrane signal of DHHC5 in (C and D), ****=p<0.001 t-test, control 
siRNA n=23, Golga7b siRNA n=23.   
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Data information: All N numbers refer to the number of cells imaged and quantified, all experiments 
repeated 4 times. Error bars represent s.e.m. All scale bars 10µm. 
 
Figure 4: Proteomic analysis of context-dependent DHHC5-associated protein complexes.  
(A) FLAG-DHHC5 immunoprecipitations were performed using lysates from Hela cells co-expressing 
either wild-type (WT) or palmitoylation deficient mutant (m) Golga7b. The interaction of DHHC5 with 
its substrate Flot2 was measured by immunoblotting and is significantly reduced in the presence of 
palmitoylation deficient mutant Golga7b, quantification normalised to input, *=p<0.05, ratio paired t-
test, n=3.  
(B) Venn diagram comparing the overlap of numbers of proteins immunoprecipitated when FLAG-
DHHC5 is expressed alone or co-expressed with either WT or mutant Golga7b. IF images are taken 
from figures EV2 and EV3 to illustrate DHHC5 localisation.  
(C) Volcano plot of DHHC5 interactors from AP-MS analysis from HeLa cells co-expressing FLAG-DHHC5 
and WT Golga7b highlighting interacting proteins involved in clathrin-mediated endocytosis, cell:cell 
adhesion and known substrates of DHHC5.  
(D) Validation of novel DHHC5 interactors by co-IP: immunoblots of Dsg2from Hela cells co-expressing 
DHHC5 and either Wild-type (WT) or mutant (m) Golga7b and quantification normalised to input, 
*=p<0.05, ratio paired t-test, n=3.  
(E) Co-IP immunoblots of clathrin heavy chain from Hela cells co-expressing DHHC5 and either wild-
type (WT) or mutant (m) Golga7b and quantification normalised to input, *=p<0.05, ratio paired t-
test, n=3.  
(F) Co-IP immunoblots of ZO-1 protein from Hela cells co-expressing DHHC5 and either wild-type (WT) 
or mutant (m) Golga7b and quantification normalised to input, **=p<0.01 ratio paired t-test, n=3.  
(G) Bar graph comparing the number of the cell:cell adhesion proteins identified in each protein 
interaction dataset. All scale bars 10Pm. All error bars represent s.e.m. 
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Figure 5: Inhibition of endocytosis restores DHHC5 to the plasma membrane in the presence of 
mutant Golga7b.  
(A) 30 minute DMSO treatment of HeLa cells co-expressing WT DHHC5 (FLAG tagged) and mutant 
Golga7b (HA tagged).  
(B) 30 minute Dynasore treatment (25µM) of HeLa cells co-expressing WT DHHC5 (FLAG tagged) and 
mutant Golga7b (HA tagged).  
(C) Non-targeting control siRNA treatment (10nM) of HeLa cells expressing mutant Golga7b (HA 
tagged). Images are detecting endogenous DHHC5 and the HA tagged Golga7b  
(D) AP2µ siRNA treatment (10nM) of HeLa cells that were subsequently transfected with mutant 
Golga7b (HA tagged). Images are detecting endogenous DHHC5 and the HA tagged Golga7b.  
(E) Quantification of plasma membrane signal of DHHC5 in (A and B). ****=p<0.001, unpaired t-test. 
N=37, +Dynasore. N=28, +DMSO.   
(F) Quantification of plasma membrane signal of DHHC5 in (C and D). ****=p<0.001, unpaired t-test. 
All scale bars 10Pm.  
(G) Biotin endocytosis assays of HeLa cells with endogenous DHHC5, over-expression of DHHC5 alone, 
co-expression of DHHC5 and WT Golga7b, co-expression of DHHC5 and mutant Golga7b or expression 
of the DHHC5 C-terminal mutant. Biotinylated cell surface proteins endocytosed within 15 minutes 
were purified using streptavidin resin and blots probed with an antibody to DHHC5. The lack of signal 
in the pull-down of the DHHC5 C-terminal mutant or when DHHC5 and WT Golga7b are co-expressed 
indicates that DHHC5 is stabilised at the plasma membrane in these conditions. The robust signal in 
the pull-down of endocytosed proteins from cells co-expressing DHHC5 and mutant Golga7b shows a 
high rate of endocytosis of DHHC5 in this condition. N=3, *=p<0.05, paired t test" 
Data information: All N numbers refer to the number of cells imaged and quantified, all experiments 
repeated 3 times. Error bars represent s.e.m. 
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Figure 6: Desmogelin-2 palmitoylation by DHHC5/Golga7b regulates its plasma membrane 
localisation and incorporation into desmosomes.  
(A)  ABE purifications from HeLa cells treated with 10nM non-targeting siRNA (nt siRNA) or DHHC5 
siRNA were immunoblotted for Dsg2. Loss of the band in the +HA pull-down in the DHHC5 siRNA 
condition shows that Dsg2 palmitoylation is dependent on DHHC5.  
(B) Confocal images of DHHC5 and Dsg2 in nt siRNA treated A431 cells three hours after calcium was 
reintroduced to the media in calcium switch experiments.  
(C) Confocal images of DHHC5 and Dsg2 in DHHC5 depleted A431 cells three hours after calcium was 
reintroduced to the media in calcium switch experiments.  
(D) Confocal images of DHHC5, Dsg2 and Golga7b in Golga7b depleted A431 cells three hours after 
calcium was reintroduced to the media in calcium switch experiments. See Appendix Figure S6 for 
quantification of data in panels B-D. 
(E) Immunoblots and quantification of Dsg2 pulled-down in cell surface biotinylation assays in nt 
siRNA, DHHC5 siRNA or Golga7b siRNA treated conditions. Quantification of the intensity of the DSG2 
signal in the pulldown is normalised to input. A significant reduction of cell surface Dsg2 occurs when 
DHHC5 or Golga7b are depleted by siRNA. *=p<0.05, paired t-test. N=4, Error bars represent s.e.m.  
(F) Immunoblot of an ABE purification for Dsg2 in cells with either normal media or low calcium (5µM 
calcium) conditions, with quantification of the intensity of the DSG2 signal in the pulldown normalised 
to input. There is a significant reduction in the Dsg2 signal in the +HA pull-down from low calcium cells 
showing that Dsg2 is significantly less palmitoylated in this condition. *=p<0.05, paired t-test, N=4, 
error bars represent s.e.m. All scale bars 10Pm. 
 
Figure 7: Cell adhesion is regulated by DHHC5/Golga7b.  
(A) 10x brightfield images of A431 cells treated with non-targeting siRNA at time 0 (left) and after 48 
hours (right) of 5 ng/ml EGF treatment.  
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(B) 10x brightfield images of A431 cells treated with DHHC5 siRNA at time 0 (left) and after 48 hours 
(right) of 5ng/ml EGF treatment.  
(C) Quantification of cell scattering of A431 cells, showing a significant increase in cell scatter after 48 
hours of DHHC5 knockdown and therefore a decrease in cell adhesion was observed. N=3 individual 
repeats, n=31 fields of view. **= p<0.005, unpaired t-test.  
(D) 10x brightfield images of A431 cells treated with non-targeting siRNA at time 0 (left) and after 48 
hours (right) of 5ng/ml EGF treatment.  
(E)  10x brightfield images of A431 cells treated with Golga7b siRNA at time 0 (left) and after 48 hours 
(right) of 5ng/ml EGF treatment.  
(F) Quantification of cell scattering of A431 cells, showing a significant increase in cell scatter after 48 
hours of Golga7b knockdown and therefore a decrease in cell adhesion, was observed.  N=3 individual 
repeats, n=31 fields of view. **= p<0.005, unpaired t-test.  
(G) Plot showing the resistance of A431 cells from a trans-epithelial electrical resistance assay treated 
with either DHHC5 siRNA, Golga7b siRNA or non-targeting siRNA. A significant reduction in TEER 
demonstrates a decrease in cell adhesion after both DHHC5 and Golga7b depletion. N=12, 
****=p<0.001, unpaired t-test, ***=p<0.01, unpaired t-test.  
Data information: Error bars represent s.e.m.   
 
Figure 8: Proposed model of how palmitoylation of Golga7b regulates plasma membrane 
localisation of DHHC5 
 
Extended View Figure legends 
Figure EV1: Reciprocal DHHC5 and Golga7b co-IP in brain tissue lysates  
(A) DHHC5 immunoblot of a Golga7b immunoprecipitation from mouse forebrain extract.  
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(B) Golga7b immunoblot of a DHHC5 immunoprecipitation from mouse forebrain extract.  
(C) Immunoblot of an ABE assay of Golga7b from mouse forebrain extract showing a hydroxylamine 
sensitive signal for Golga7b confirming that it is palmitoylated in vivo. 
 
Figure EV2: Over-expression of DHHC5 causes a localisation defect.  
(A) Confocal images of endogenous DHHC5 in HeLa cells.  
(B) Confocal images of HeLa cells expressing WT DHHC5 C-terminally tagged with a FLAG epitope.  
(C) Confocal images of HeLa cells expressing a C-terminally FLAG tagged catalytic mutant of DHHC5 
where the active site cysteine of DHHC5 has been replaced with a serine (DHHS5).  
(D) Confocal microscopy images of HeLa cells expressing DHHC5 with the three palmitoylated 
cysteines in the C-terminal tail mutated to serine residues. Antibody detecting endogenous FLAG 
epitope.  
(E) Quantification of membrane signal of DHHC5 seen in (A-D). All experiments repeated 3 individual 
times, all n numbers refer to the number of cells quantified. Endogenous DHHC5, n=45, DHHC5, n=48, 
DHHS5 only, n=38, C-terminal mutant, n=35 ****=p<0.001, unpaired t-test. Error bars represent 
s.e.m.  All scale bars 10Pm. 
 
Figure EV3: Regulation of DHHC5 localisation by palmitoylation of Golga7b and the C-terminus of 
DHHC5.  
(A) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and DHHC5 (2nd column), 
with a merged image (3rd column).  
(B) Confocal images of HeLa cells co-expressing palmitoylation-deficient mutant Golga7b (1st column) 
and DHHC5 (2nd column), with a merged image (3rd column).  
(C) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and DHHS5 (2nd column), 
with a merged image (3rd column).  
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(D) Confocal images of HeLa cells co-expressing palmitoylation-deficient mutant Golga7b (1st column) 
and DHHS5 (2nd column), with a merged image (3rd column).  
(E) Confocal images of HeLa cells co-expressing WT Golga7b (1st column) and DHHC5 C-terminal 
palmitoylation-deficient mutant (2nd column), with a merged image (3rd column).  
(F) Confocal images of HeLa cells co-expressing palmitoylation-deficient mutant Golga7b (1st column) 
and DHHC5 C-terminal palmitoylation-deficient mutant (2nd column), with a merged image (3rd 
column).  
(G) Quantification of the membrane signal of DHHC5 in each of the images (A-F).  ****=p<0.001, n.s. 
= not significant, unpaired t-test. N=49, DHHC5 + WT Golga7b. N=53, DHHC5 + mutant Golga7b. N=40, 
DHHS5 + WT Golga7b. N=28, DHHS5 + Golga7b mutant. N=42, C-terminal mutant + WT Golga7b. N=31, 
C-terminal mutant + mutant Golga7b. All experiments repeated 3 individual times, N number refers 
to the number of cells, error bars represent s.e.m.  
 
Figure EV4: Calcium switch of A431 cells treated with non-targeting siRNA.  
(A) Time zero after calcium chloride addition.  
(B) 30 minutes after calcium chloride addition.  
(C) 1 hour after calcium chloride addition.  
(D) 3 hours after calcium chloride addition.  
(E) Percentage of Dsg2 signal seen at the plasma membrane at each time point, *=p<0.05, unpaired t 
test. N=3 individual experiments, n=25 cells at 0 time point, n=30 cells at 0 time point, n=34 cells 
at 1 hour time point, n=26 cells at 3 hour time point.  Error bars represent s.e.m.  All scale bars 
10Pm. 
 
Figure EV5: Calcium switch of A431 cells treated with DHHC5 siRNA.  
(A) Time zero after calcium chloride addition.  
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(B) 1 hour after calcium chloride addition.  
(C) 3 hours after calcium chloride addition.  
(D) Percentage of Dsg2 signal seen at the plasma membrane at each time point N=3 individual 
experiments, n=23 cells at 0 time point, n=16 cells at 1 hour time point, n=24 cells at 3 hour time point. 
Error bars represent s.e.m.  All scale bars 10Pm. 
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Appendix Figure S1: Efficiency of protein depletion with siRNAs. (A) Immunoblots from HeLa
cells treated with 10nM DHHC5 siRNA (right lane) or non-targeting siRNA (left lane).
Quantification normalised to actin signal. Time of treatment for siRNA is 72 hours. N=3. (B)
Immunoblot from HeLa cells treated with 20nM Golga7b siRNA (right lane) or non-targeting siRNA
(left lane). Quantification normalised to actin signal. Time of treatment for siRNA is 72 hours. N=3.
(C) Immunoblot from HeLa cells treated with 15nM AP2m siRNA (right lane) or non-targeting
siRNA (left lane). Quantification normalised to actin signal. Time of treatment for siRNA is 72
hours. N=3. (D) Immunoblot from A431 cells treated with 10nM DHHC5 siRNA (right lane) or non-
targeting siRNA (left lane). Quantification normalised to actin signal. Time of treatment for siRNA
is 24 hours. N=3. (E) Expression of all 5 constructs used in this work.
Appendix Figure S2
Appendix Figure S2: Golga7 is unable to rescue the DHHC5 localisation phenotype caused
by depletion of Golga7b. (A) Confocal images of endogenous Golga7b and DHHC5 in HeLa cell
treated with Golga7b siRNA and expressing Golga7. (B) Quantification of the plasma membrane
signal of DHHC5 in A, ****=p<0.001 t-test, control siRNA n=23, Golga7b siRNA n=23, Golga7b
siRNA + Golga7 n=27.
Appendix Figure S3
Appendix Figure S3: DHHC5 palmitoylates plakophilin 3. ABE immunoblot for plakophilin-3
(pkp3) from HeLa cells treated with 10nM non-targeting siRNA (nt siRNA) or DHHC5 siRNA. Loss
of the band in the +HA pulldown in the DHHC5 siRNA condition shows a DHHC5-dependent loss
of pkp3 palmitoylation.
Appendix Figure S4
Appendix Figure S4: Depletion of DHHC5 does not abolish palmitoylation of Flotillin-2.
Flotillin-2 Immunoblotting of a PEG switch assay performed using lysates from HeLa cells treated
with non-targeting siRNA (nt siRNA) or with DHHC5 siRNA (DHHC5 siRNA). Apo = unmodified
protein, * = singly palmitoylated, ** = dually palmitoylated, *** = triply palmitoylated.
Appendix Figure S5
Appendix Figure S5: Palmitoylation by DHHC5 drives Golga7b plasma membrane
localisation. Graph showing quantification of plasma membrane signal of mutant Golga7b
when co-expressed with WT DHHC5, WT Golga7b when co-expressed with catalytically
inactive DHHS5 and WT Golga7b when co-expressed with WT DHHC5. ****=p<0.001,
unpaired t-test, error bars represent s.e.m. WT DHHC5 + mutant Golga7b, n=34, catalytic
mutant DHHC5 + mutant Golga7b, n=27, WT DHHC5 + WT Golga7b, n=26.
Appendix Figure S6
Appendix Figure S6: Desmogelin-2 palmitoylation by DHHC5/Golga7b regulates its
plasma membrane localisation. Quantification of the percentage of total signal DSG2 seen at
the plasma membrane and within the cell (internal) after 3 hours in calcium switch experiments
in either nt siRNA or DHHC5 siRNA conditions shown in Figure 6B-D. ****=p<0.001, unpaired
t-test. N=24,
